Latus Bio
Reviewed active Updated May 5, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Latus Bio is a clinical-stage gene therapy company developing AAV-based therapies for central nervous system and rare diseases, with offices in Philadelphia, PA and Boston, MA (Seaport) 1 2. The company was founded by Beverly Davidson, Ph.D., a gene therapy researcher at Children’s Hospital of Philadelphia who received the American Society of Gene & Cell Therapy’s Outstanding Achievement Award in 2026 4. P. Peter Ghoroghchian, M.D., Ph.D., serves as CEO 1.
Latus’s lead programs are LTS-201, an AAV gene therapy targeting MSH3 expression for Huntington’s disease (IND expected Q3 2026), and LTS-101, an AAV gene therapy encoding the TPP1 gene for CLN2 (Batten) disease, which received FDA IND clearance in December 2025 along with Orphan Drug, Rare Pediatric Disease, and Fast Track designations 4. The company’s strategy targets “large-rare and broader CNS indications” with potential applications also in kidney, eye, heart, and muscle diseases 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-05-04 | Series A Extension | $43M | 8VC | DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, Hatch BioFund, Korea Development Bank, Helen’s Pink Sky Foundation 1 3 |
The May 2026 announcement disclosed a $43M Series A extension that, combined with the prior $54M Series A, brought total Series A financing to $97M 1 3. The Series A extension is the most recent verified round; the round was widely covered as a “$42M” raise in tech press 3, while the company’s official announcement stated $43M 1.
What Investors Say
Francisco Gimenez, partner at 8VC (lead of the Series A extension):
“The Company’s strategy to focus on large-rare and broader CNS indications…positions it to address longstanding limitations to gene therapy access.” 1
What Founders Say
CEO P. Peter Ghoroghchian, on the financing:
“This financing…supports the advancement of our clinical pipeline and strategy to expand gene therapy to larger diseases.” 1
Sources
-
PharmiWeb / BusinessWire, “Latus Bio Announces $97 Million Series A Financing to Expand the Reach of Gene Therapy to Larger Populations,” May 4, 2026. https://www.pharmiweb.com/press-release/2026-05-04/latus-bio-announces-97-million-series-a-financing-to-expand-the-reach-of-gene-therapy-to-larger-pop↩↩↩↩↩↩↩↩
-
Citybiz, “Latus Bio Raises $97M Series A to Advance Scalable Gene Therapies,” May 2026. https://www.citybiz.co/article/840955/latus-bio-raises-97m-series-a-to-advance-scalable-gene-therapies/↩
-
STAT News, “Biotech raises $42 million to run Huntington’s disease trial,” May 4, 2026. https://www.statnews.com/2026/05/04/biotech-startup-latus-bio-raises-42-million-run-huntingtons-trial/↩↩↩
-
BioAdvance, “Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 Disease,” April 28, 2026. https://bioadvance.com/latus-bio-to-present-new-data-at-asgct-2026-supporting-investigational-gene-therapy-approaches-for-huntingtons-disease-and-cln2-disease/↩↩